fluoxetine has been researched along with 2019 Novel Coronavirus Disease in 19 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety." | 5.69 | Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial. ( Ala, S; Alizadeh Arimi, F; Elyasi, F; Ghasemian, R; Mehravaran, H; Moosazadeh, M; Sedighi, F; Zarghami, M, 2023) |
| "Fluvoxamine was not associated with increased serious adverse events." | 3.01 | Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis. ( Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023) |
| "The current 2019 novel coronavirus disease (COVID-19), an emerging infectious disease, is undoubtedly the most challenging pandemic in the 21st century." | 2.72 | Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives? ( Pashaei, Y, 2021) |
| "Pandemic outbreaks of viruses such as influenza virus or SARS-CoV-2 are associated with high morbidity and mortality and thus pose a massive threat to global health and economics." | 1.72 | 3D ( Balkema-Buschmann, A; Barth, P; Brunotte, L; de Witt, M; Faist, A; Kummer, S; Ludwig, S; Rescher, U; Schloer, S; Treuherz, D; Wälzlein, JH; Wiebe, K; Wiewrodt, R; Wunderlich, K, 2022) |
| "Fluoxetine use was associated with an important (70%) decrease of mortality (OR [95% CI] 0." | 1.62 | Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study. ( Holló, A; Juhász, D; Németh, JP; Németh, ZK; Szûcs, A; Vitrai, J, 2021) |
| "Fluoxetine treatment resulted in a decrease in viral protein expression." | 1.62 | The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue. ( Bodem, J; Danov, O; Geiger, N; Hilpert, H; Kirschner, L; Oberwinkler, H; Seibel, J; Sewald, K; Steinke, M; Zimniak, M, 2021) |
| "Depression is responsible for 800 000 deaths worldwide, a number that will rise significantly due to the COVID-19 pandemic." | 1.62 | Withanone Ameliorates Stress Symptoms in Caenorhabditis Elegans by Acting through Serotonin Receptors. ( Efferth, T; Naß, J, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 19 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Oskotsky, T | 1 |
| Maric, I | 1 |
| Tang, A | 1 |
| Oskotsky, B | 1 |
| Wong, RJ | 1 |
| Aghaeepour, N | 1 |
| Sirota, M | 1 |
| Stevenson, DK | 1 |
| Németh, ZK | 1 |
| Szûcs, A | 1 |
| Vitrai, J | 1 |
| Juhász, D | 1 |
| Németh, JP | 1 |
| Holló, A | 1 |
| Fritz, BA | 1 |
| Hoertel, N | 1 |
| Lenze, EJ | 2 |
| Jalali, F | 1 |
| Reiersen, AM | 2 |
| Schloer, S | 2 |
| Treuherz, D | 1 |
| Faist, A | 1 |
| de Witt, M | 1 |
| Wunderlich, K | 1 |
| Wiewrodt, R | 1 |
| Wiebe, K | 1 |
| Barth, P | 1 |
| Wälzlein, JH | 1 |
| Kummer, S | 1 |
| Balkema-Buschmann, A | 1 |
| Ludwig, S | 2 |
| Brunotte, L | 2 |
| Rescher, U | 2 |
| de Melo Martins, GM | 1 |
| Petersen, BD | 1 |
| Rübensam, G | 1 |
| da Silva, JMK | 1 |
| Gaspary, KV | 1 |
| Wiprich, MT | 1 |
| Altenhofen, S | 1 |
| Bonan, CD | 1 |
| Tronco Pauletto, PJ | 1 |
| Omage, FB | 1 |
| Delgado, CP | 5 |
| Nogara, PA | 4 |
| Teixeira Rocha, JB | 1 |
| Pauletto, P | 3 |
| Bortoli, M | 3 |
| Bright, FO | 3 |
| Orian, L | 3 |
| da Rocha, JBT | 4 |
| Deng, J | 1 |
| Rayner, D | 1 |
| Ramaraju, HB | 1 |
| Abbas, U | 1 |
| Garcia, C | 1 |
| Heybati, K | 1 |
| Zhou, F | 1 |
| Huang, E | 1 |
| Park, YJ | 1 |
| Moskalyk, M | 1 |
| Izumi, Y | 1 |
| Mennerick, SJ | 1 |
| Zorumski, CF | 1 |
| Pauletto, PJT | 1 |
| Sedighi, F | 1 |
| Zarghami, M | 1 |
| Alizadeh Arimi, F | 1 |
| Moosazadeh, M | 1 |
| Ala, S | 1 |
| Ghasemian, R | 1 |
| Mehravaran, H | 1 |
| Elyasi, F | 1 |
| Diesendorf, V | 1 |
| Roll, V | 1 |
| Geiger, N | 2 |
| Fähr, S | 1 |
| Obernolte, H | 1 |
| Sewald, K | 2 |
| Bodem, J | 2 |
| Lim, J | 1 |
| Lee, J | 1 |
| Goretzko, J | 1 |
| Mecate-Zambrano, A | 1 |
| Korthals, N | 1 |
| Gerke, V | 1 |
| Taylor, R | 1 |
| Bodoukhin, N | 1 |
| Botros, M | 1 |
| Luca, L | 1 |
| Zimniak, M | 1 |
| Kirschner, L | 1 |
| Hilpert, H | 1 |
| Danov, O | 1 |
| Oberwinkler, H | 1 |
| Steinke, M | 1 |
| Seibel, J | 1 |
| Naß, J | 1 |
| Efferth, T | 1 |
| Pashaei, Y | 1 |
| Khosravi, M | 1 |
4 reviews available for fluoxetine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Topics: COVID-19; Fluoxetine; Fluvoxamine; Humans; Selective Serotonin Reuptake Inhibitors | 2023 |
Acid sphingomyelinase (ASM) and COVID-19: A review of the potential use of ASM inhibitors against SARS-CoV-2.
Topics: Ceramides; COVID-19; Fluoxetine; Humans; SARS-CoV-2; Sphingomyelin Phosphodiesterase | 2023 |
Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
Topics: Anti-Inflammatory Agents; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Fluoxetine; Humans; | 2021 |
Candidate Psychotropics against SARS - CoV - 2: A Narrative Review.
Topics: COVID-19; Escitalopram; Fluoxetine; Humans; Psychotropic Drugs; SARS-CoV-2 | 2022 |
1 trial available for fluoxetine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial.
Topics: Antidepressive Agents, Second-Generation; Anxiety; C-Reactive Protein; COVID-19; Depression; Double- | 2023 |
14 other studies available for fluoxetine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Citalopram; COVID-19; Cytokines; Female; Fluoxetine; Fluvoxamine | 2021 |
Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study.
Topics: Adult; Case-Control Studies; COVID-19; Fluoxetine; Humans; Reproducibility of Results; Retrospective | 2021 |
Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2.
Topics: Adult; Antidepressive Agents; COVID-19; Emergency Service, Hospital; Fluoxetine; Humans; Outpatients | 2022 |
3D
Topics: Animals; Antiviral Agents; COVID-19; Fluoxetine; Humans; Influenza A virus; Influenza, Human; Interf | 2022 |
Physical exercise prevents behavioral alterations in a reserpine-treated zebrafish: A putative depression model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Behavior, Animal; COVID-19; Depressi | 2022 |
Topics: Antidepressive Agents; Antiviral Agents; Citalopram; COVID-19; Fluoxetine; Humans; Molecular Docking | 2023 |
Topics: Antidepressive Agents; Ceramides; COVID-19; Fluoxetine; Humans; Saposins; SARS-CoV-2; Sphingomyelin | 2023 |
Topics: Antidepressive Agents; Ceramides; COVID-19; Fluoxetine; Humans; Saposins; SARS-CoV-2; Sphingomyelin | 2023 |
Topics: Antidepressive Agents; Ceramides; COVID-19; Fluoxetine; Humans; Saposins; SARS-CoV-2; Sphingomyelin | 2023 |
Topics: Antidepressive Agents; Ceramides; COVID-19; Fluoxetine; Humans; Saposins; SARS-CoV-2; Sphingomyelin | 2023 |
SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids.
Topics: Animals; Anti-Inflammatory Agents; COVID-19; Drug Inverse Agonism; Fluoxetine; Fluvoxamine; Hippocam | 2023 |
Drug-induced phospholipidosis is not correlated with the inhibition of SARS-CoV-2 - inhibition of SARS-CoV-2 is cell line-specific.
Topics: Antiviral Agents; Cell Line; Chloroquine; COVID-19; Fluoxetine; Humans; SARS-CoV-2; Tilorone | 2023 |
Current laboratory diagnosis of coronavirus disease 2019.
Topics: Antidepressive Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coronavirus; Coronavi | 2020 |
Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine.
Topics: Antidepressive Agents; Antiviral Agents; Betacoronavirus; Cell Line; Coronavirus Infections; COVID-1 | 2020 |
Joy Journal: A Behavioral Activation Technique Used in the Treatment of Late-Life Depression Associated With Hopelessness During the COVID-19 Pandemic.
Topics: Aged; Antidepressive Agents; Aripiprazole; Cognitive Behavioral Therapy; COVID-19; Depressive Disord | 2021 |
The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.
Topics: Animals; Antiviral Agents; Cell Line; Cells, Cultured; COVID-19; COVID-19 Drug Treatment; Fluoxetine | 2021 |
Withanone Ameliorates Stress Symptoms in Caenorhabditis Elegans by Acting through Serotonin Receptors.
Topics: Animals; Animals, Genetically Modified; Antidepressive Agents; Caenorhabditis elegans; COVID-19; Dep | 2021 |